Cns Pharmaceuticals Inc (NASDAQ: CNSP) has experienced a decline in its stock price by -7.87 compared to its previous closing price of 2.67. However, the company has seen a gain of 48.19% in its stock price over the last five trading days. Accesswire reported 2023-09-05 that Live webcast presentation on Wednesday, September 13th at 10:30 AM ET HOUSTON, TX / ACCESSWIRE / September 5, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held in New York, NY on Wednesday, September 13, 2023 at 10:30 AM ET.

Is It Worth Investing in Cns Pharmaceuticals Inc (NASDAQ: CNSP) Right Now?

and a 36-month beta value of 1.25.

Top 5 Artificial Intelligence Stocks to Buy for 2024

By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it. According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"


The public float for CNSP is 5.13M, and at present, short sellers hold a 0.93% of that float. On November 21, 2023, the average trading volume of CNSP was 135.25K shares.

CNSP’s Market Performance

The stock of Cns Pharmaceuticals Inc (CNSP) has seen a 48.19% increase in the past week, with a 21.78% rise in the past month, and a 41.38% gain in the past quarter. The volatility ratio for the week is 19.05%, and the volatility levels for the past 30 days are at 15.10% for CNSP. The simple moving average for the past 20 days is 26.09% for CNSP’s stock, with a 42.30% simple moving average for the past 200 days.

CNSP Trading at 56.63% from the 50-Day Moving Average

After a stumble in the market that brought CNSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.71% of loss for the given period.

Volatility was left at 15.10%, however, over the last 30 days, the volatility rate increased by 19.05%, as shares surge +17.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +69.66% upper at present.

During the last 5 trading sessions, CNSP rose by +48.19%, which changed the moving average for the period of 200-days by +0.41% in comparison to the 20-day moving average, which settled at $1.97. In addition, Cns Pharmaceuticals Inc saw 2.50% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CNSP starting from Downs Christopher, who purchase 27,000 shares at the price of $1.27 back on Aug 22. After this action, Downs Christopher now owns 36,772 shares of Cns Pharmaceuticals Inc, valued at $34,177 using the latest closing price.

Climaco John M, the Chief Executive Officer of Cns Pharmaceuticals Inc, purchase 2,750 shares at $1.80 during a trade that took place back on Aug 16, which means that Climaco John M is holding 49,010 shares at $4,944 based on the most recent closing price.

Stock Fundamentals for CNSP

The total capital return value is set at -192.03, while invested capital returns managed to touch -207.04. Equity return is now at value -570.59, with -317.24 for asset returns.

Based on Cns Pharmaceuticals Inc (CNSP), the company’s capital structure generated 5.04 points at debt to equity in total, while total debt to capital is 4.80.

The liquidity ratio also appears to be rather interesting for investors as it stands at 2.55.


To sum up, Cns Pharmaceuticals Inc (CNSP) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.